Cadila Pharmaceuticals

From Wikipedia, the free encyclopedia
Not to be confused with Cadila Healthcare.

Cadila Pharmaceuticals Limited
TypePrivate company
IndustryPharmaceuticals
Founded1951
FounderIndravadan Modi
Headquarters
Ahmedabad, Gujarat
,
India
Key people
Dr. Rajiv Modi
(Chairman and Managing Director)
ProductsAPIs, Generic drugs
ServicesContract Research, Contract Manufacturing
Number of employees
8000
SubsidiariesIRM Ltd
Websitewww.cadilapharma.com

Cadila Pharmaceuticals is an Indian multinational pharmaceutical group based in Ahmedabad, Gujarat, India. With more than 6 decades of experience, the company's integrated operations focus on manufacturing products ranging from API's-Intermediates, finished formulations, OTC-Food Supplements, Biotechnology Products and pharmaceutical Machinery. Cadila Pharmaceuticals manufacturing facilities are approved by International bodies such as WHO-GMP, UK-MHRA, USFDA-API, TGA-Australia, and AIFA-Italy. The company's international operation of is spread across 58 countries including the Americas, Japan, Asia, CIS and Africa.[1]

History[]

Indravadan Modi, Founder

Cadila Laboratories[]

In 1951 Indravadan A Modi had quit his job as a chemist in a Mumbai firm to start Cadila Laboratories with childhood friend Ramanbhai Patel. The company that started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation had come a long way.[2]

1995: Birth of Cadila Pharmaceuticals[]

The Modi and Patel families decided to split the business in 1995, two entities were formed - Cadila Pharmaceuticals Ltd (owned and controlled by Shri. I A Modi and his son Dr. Rajiv Modi) and Cadila Healthcare (owned by Shri. Ramanbhai Patel and his son Pankaj Patel family). Rajiv Modi and I A Modi worked closely to run Cadila Pharma, now considered one of the largest privately-held pharma companies in the country.[2]

Operations[]

Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa (Ethiopia) and 2 API manufacturing facilities are located at Ankleshwar, Gujarat. The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.[3]

Research[]

Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 1,05,000 sq. ft. area at Dholka, Gujarat, India which is manned by 300 scientists.

The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma. The company has submitted ten ANDAs.[4] Cadila Pharmaceuticals has connections with various institutions for research; Department of Biotechnology, UDSC, New Delhi; IISc, Bangalore; Lala Ram Sarup Institute of TB & Respiratory diseases, New Delhi; RRL, Jammu; CSIR, New Delhi; CDRI, Lucknow; Advanced Transfusion Medicine Research Foundation, Ahmedabad; National Institute of Immunology, New Delhi; Institute of Microbial Technology, Chandigarh; Talwar Research Foundation, New Delhi and Trieste, Italy.[5]

Products and services[]

Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase and Hyaluronic Acid products. The company was also the first in the world to introduce Rabeprazole in IV form – ‘Rabeloc’.[6] In 2009, the world’s first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis – ‘Risorine’[7] and world's first drug combination for prevention of Cardiovascular Diseases – ‘Polycap’ were introduced by Cadila Pharmaceuticals.[8] For the patients suffering from Non Small Cell Lung Cancer (NSCLC), company has recently introduced ‘Mycidac-C’ - first in the class active immunotherapy as well as drug targeting Desmocollin.[9] Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D, Mycobutol and Sepsivac.

Alliances[]

In 2019, Cadila Pharmaceuticals formed a partnership with Norwegian start-up, Serca Pharmaceuticals to develop new treatment for heart patients.[10]

Awards and Recognition[]

Most Trusted Companies of 2008, Sara Media and Zee Business[11]

WorldStar Packaging Award, 2018[12]

TISS LeapVault CLO Award, 2019[13]

Observenow Future of Workplace Award, 2019[14]

Great Place to Work Certified, 2020[15]

References[]

  1. ^ "Cadila Pharmaceuticals Ltd". CPhI Worldwide - Uniting the Pharmaceutical Industry. 13 September 2018.
  2. ^ a b Das, Sohini (28 January 2014). "Carrying the legacy forward: Rajiv Modi" – via Business Standard.
  3. ^ Financial Express 28 January 2013
  4. ^ "Welcome to India in Business". www.indiainbusiness.nic.in. Archived from the original on 7 July 2014. Retrieved 24 March 2014.
  5. ^ "Cadila Pharma". Archived from the original on 21 April 2014. Retrieved 24 March 2014.
  6. ^ Bureau, Our Regional (16 July 2004). "Cadila Pharma unveils acidity drug in IV form" – via Business Standard.
  7. ^ "Cadila launches new drug for TB treatment". dna. 31 October 2009.
  8. ^ "Cadila Pharmaceuticals launches Polycap, which reduces cardiovascular and stroke risk substantially". The Financial Express. 2 April 2009.
  9. ^ "Economic Times 21 November 2013".
  10. ^ "Cadila Pharma inks pact with Norwegian start-up to develop new treatment for heart patients". @businessline. Retrieved 11 January 2019.
  11. ^ "Indravadan A Modi: The medicine man of India". DeshGujarat. 26 November 2012. Retrieved 16 October 2019.
  12. ^ "Calcirol Softgel | Worldstar". www.worldstar.org. Retrieved 16 October 2019.
  13. ^ "Cadila Pharma bags TISS LeapVault CLO awards in two categories". Express Pharma. 9 August 2019. Retrieved 16 October 2019.
  14. ^ Bureau, The Pharma Times News (14 September 2019). "Cadila Pharma wins 'ObserveNow Future of Workplace Award'". The Pharma Times | Pharma & Health Care News Portal. Retrieved 16 October 2019.
  15. ^ "Cadila Pharmaceuticals Awarded Great Place To Work Certificate". The Week. Retrieved 17 March 2020.
Retrieved from ""